-
1
-
-
0035093810
-
Diabetes mellitus: A hypercoagulable state
-
Carr ME: Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001, 15:44-54.
-
(2001)
J Diabetes Complications
, vol.15
, pp. 44-54
-
-
Carr, M.E.1
-
2
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
-
Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
-
(1998)
N Engl J Med
, vol.339
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
-
3
-
-
0034994570
-
Healthy lifestyles in Europe: Prevention of obesity and type II diabetes by diet and physical activity
-
Astrup A: Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 2001, 4:499-515.
-
(2001)
Public Health Nutr
, vol.4
, pp. 499-515
-
-
Astrup, A.1
-
4
-
-
18644365016
-
Insulin resistance in type 2 diabetes - role of the adipokines
-
Arner P: Insulin resistance in type 2 diabetes - role of the adipokines. Curr Mol Med 2005, 5:333-339.
-
(2005)
Curr Mol Med
, vol.5
, pp. 333-339
-
-
Arner, P.1
-
5
-
-
0030778116
-
The prevention and treatment of obesity. Application to type 2 diabetes
-
Maggio CA, Pi-Sunyer FX: The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997, 20:1744-1766.
-
(1997)
Diabetes Care
, vol.20
, pp. 1744-1766
-
-
Maggio, C.A.1
Pi-Sunyer, F.X.2
-
6
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
7
-
-
1042280201
-
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report
-
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO: Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004, 27:17-20.
-
(2004)
Diabetes Care
, vol.27
, pp. 17-20
-
-
Koro, C.E.1
Bowlin, S.J.2
Bourgeois, N.3
Fedder, D.O.4
-
8
-
-
0033578476
-
Pharmacologic therapy for type 2 diabetes mellitus
-
DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
-
(1999)
Ann Intern Med
, vol.131
, pp. 281-303
-
-
DeFronzo, R.A.1
-
9
-
-
0022617246
-
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
-
Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
-
(1986)
Diabetologia
, vol.29
, pp. 46-52
-
-
Nauck, M.1
Stockmann, F.2
Ebert, R.3
Creutzfeldt, W.4
-
10
-
-
0038497464
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
-
Kolterman OG, Buse JB, Fineman MS, et al.: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 3082-3089
-
-
Kolterman, O.G.1
Buse, J.B.2
Fineman, M.S.3
-
11
-
-
0027248866
-
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
-
Nauck MA, Kleine N, Orskov C, et al.: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
-
(1993)
Diabetologia
, vol.36
, pp. 741-744
-
-
Nauck, M.A.1
Kleine, N.2
Orskov, C.3
-
12
-
-
9944251347
-
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
-
Nystrom T, Gonon AT, Sjoholm A, Pernow J: Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005, 125:173-177.
-
(2005)
Regul Pept
, vol.125
, pp. 173-177
-
-
Nystrom, T.1
Gonon, A.T.2
Sjoholm, A.3
Pernow, J.4
-
13
-
-
12144260853
-
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
-
Bose AK, Mocanu MM, Carr RD, et al.: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
-
(2005)
Diabetes
, vol.54
, pp. 146-151
-
-
Bose, A.K.1
Mocanu, M.M.2
Carr, R.D.3
-
14
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
-
15
-
-
8544258807
-
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
-
Nystrom T, Gutniak MK, Zhang Q, et al.: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-1215.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
-
-
Nystrom, T.1
Gutniak, M.K.2
Zhang, Q.3
-
16
-
-
0037219411
-
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
-
Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
-
(2003)
Diabetes
, vol.52
, pp. 102-110
-
-
Butler, A.E.1
Janson, J.2
Bonner-Weir, S.3
-
17
-
-
0033303516
-
Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
-
Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
-
(1999)
Endocrinology
, vol.140
, pp. 5356-5363
-
-
Hansen, L.1
Deacon, C.F.2
Orskov, C.3
Holst, J.J.4
-
18
-
-
0141446228
-
Enhancing incretin action for the treatment of type 2 diabetes
-
Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
-
(2003)
Diabetes Care
, vol.26
, pp. 2929-2940
-
-
Drucker, D.J.1
-
19
-
-
0031040794
-
Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
-
Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 1997, 272:4108-4115.
-
(1997)
J Biol Chem
, vol.272
, pp. 4108-4115
-
-
Chen, Y.E.1
Drucker, D.J.2
-
20
-
-
67649331128
-
-
Amylin Pharmaceuticals Inc, Available at, Accessed on June 25, 2007
-
Amylin Pharmaceuticals Inc.: Byetta: Prescribing Information. Available at http://www.byetta.com. Accessed on June 25, 2007.
-
Byetta: Prescribing Information
-
-
-
21
-
-
0036235563
-
Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4
-
Thum A, Hupe-Sodmann K, Goke R, et al.: Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4. Exp Clin Endocrinol Diabetes 2002, 110:113-118.
-
(2002)
Exp Clin Endocrinol Diabetes
, vol.110
, pp. 113-118
-
-
Thum, A.1
Hupe-Sodmann, K.2
Goke, R.3
-
22
-
-
0035340019
-
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
-
Parkes DG, Pittner R, Jodka C, et al.: Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
-
(2001)
Metabolism
, vol.50
, pp. 583-589
-
-
Parkes, D.G.1
Pittner, R.2
Jodka, C.3
-
23
-
-
7444228521
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonyl-urea-treated patients with type 2 diabetes
-
Buse JB, Henry RR, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonyl-urea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
-
(2004)
Diabetes Care
, vol.27
, pp. 2628-2635
-
-
Buse, J.B.1
Henry, R.R.2
Han, J.3
-
24
-
-
18144401971
-
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
-
DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
-
(2005)
Diabetes Care
, vol.28
, pp. 1092-1100
-
-
DeFronzo, R.A.1
Ratner, R.E.2
Han, J.3
-
25
-
-
20544476444
-
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: A dose-ranging study
-
Poon T, Nelson P, Shen L, et al.: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005, 7:467-477.
-
(2005)
Diabetes Technol Ther
, vol.7
, pp. 467-477
-
-
Poon, T.1
Nelson, P.2
Shen, L.3
-
26
-
-
4344713643
-
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia
-
Degn KB, Brock B, Juhl CR, et al.: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397-2403.
-
(2004)
Diabetes
, vol.53
, pp. 2397-2403
-
-
Degn, K.B.1
Brock, B.2
Juhl, C.R.3
-
27
-
-
17144371646
-
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
-
Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
-
(2005)
Diabetes Care
, vol.28
, pp. 1083-1091
-
-
Kendall, D.M.1
Riddle, M.C.2
Rosenstock, J.3
-
28
-
-
26944477362
-
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial
-
Heine RJ, Van Gaal LF, Johns D, et al.: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
-
(2005)
Ann Intern Med
, vol.143
, pp. 559-569
-
-
Heine, R.J.1
Van Gaal, L.F.2
Johns, D.3
-
29
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
-
Blonde L, Klein EJ, Han J, et al.: Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 436-447
-
-
Blonde, L.1
Klein, E.J.2
Han, J.3
-
30
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
-
Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
-
(2000)
BMJ
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
31
-
-
0032902850
-
The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years
-
Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
-
(1999)
Diabetes Care
, vol.22
, pp. 233-240
-
-
Coutinho, M.1
Gerstein, H.C.2
Wang, Y.3
Yusuf, S.4
-
32
-
-
33749046314
-
Postprandial hyperglycaemia and cardiovascular complications of diabetes: An update
-
Ceriello A, Davidson J, Hanefeld M, et al.: Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006, 16:453-456.
-
(2006)
Nutr Metab Cardiovasc Dis
, vol.16
, pp. 453-456
-
-
Ceriello, A.1
Davidson, J.2
Hanefeld, M.3
-
33
-
-
22744439545
-
Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes
-
Home P: Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005, 21:989-998.
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 989-998
-
-
Home, P.1
-
34
-
-
0031880436
-
Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study
-
Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998, 21:1236-1239.
-
(1998)
Diabetes Care
, vol.21
, pp. 1236-1239
-
-
Barrett-Connor, E.1
Ferrara, A.2
-
35
-
-
0033047374
-
Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study
-
Tominaga M, Eguchi H, Manaka H, et al.: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
-
(1999)
Diabetes Care
, vol.22
, pp. 920-924
-
-
Tominaga, M.1
Eguchi, H.2
Manaka, H.3
-
36
-
-
0027365368
-
Long-term effects of change in body weight on all-cause mortality. A review
-
Andres R, Muller DC, Sorkin JD: Long-term effects of change in body weight on all-cause mortality. A review. Ann Intern Med 1993, 119:737-743.
-
(1993)
Ann Intern Med
, vol.119
, pp. 737-743
-
-
Andres, R.1
Muller, D.C.2
Sorkin, J.D.3
-
37
-
-
31644444063
-
The growing problem of obesity and the heart: The plot "thickens
-
Litwin SE: The growing problem of obesity and the heart: the plot "thickens". J Am Coll Cardiol 2006, 47:617-619.
-
(2006)
J Am Coll Cardiol
, vol.47
, pp. 617-619
-
-
Litwin, S.E.1
-
39
-
-
0025317085
-
A prospective study of obesity and risk of coronary heart disease in women
-
Manson JE, Colditz GA, Stampfer MJ, et al.: A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990, 322:882-889.
-
(1990)
N Engl J Med
, vol.322
, pp. 882-889
-
-
Manson, J.E.1
Colditz, G.A.2
Stampfer, M.J.3
-
40
-
-
0027520177
-
Body weight and mortality. A 27-year follow-up of middle-aged men
-
Lee IM, Manson JE, Hennekens CH, Paffenbarger RS Jr: Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993, 270:2823-2828.
-
(1993)
JAMA
, vol.270
, pp. 2823-2828
-
-
Lee, I.M.1
Manson, J.E.2
Hennekens, C.H.3
Paffenbarger Jr, R.S.4
-
41
-
-
0026753155
-
Beneficial health effects of modest weight loss
-
Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992, 16:397-415.
-
(1992)
Int J Obes Relat Metab Disord
, vol.16
, pp. 397-415
-
-
Goldstein, D.J.1
-
42
-
-
0033807248
-
Intentional weight loss and mortality among overweight individuals with diabetes
-
Williamson DF, Thompson TJ, Thun M, et al.: Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000, 23:1499-1504.
-
(2000)
Diabetes Care
, vol.23
, pp. 1499-1504
-
-
Williamson, D.F.1
Thompson, T.J.2
Thun, M.3
-
43
-
-
33748471110
-
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
-
Ratner RE, Maggs D, Nielsen LL, et al.: Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 419-428
-
-
Ratner, R.E.1
Maggs, D.2
Nielsen, L.L.3
-
44
-
-
33845267926
-
Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus [abstract 784]
-
Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1C, and body weight in patients with type 2 diabetes mellitus [abstract 784]. Diabetologia 2006, 49(Suppl 1):475.
-
(2006)
Diabetologia
, vol.49
, Issue.SUPPL. 1
, pp. 475
-
-
Kendall, D.M.1
Bhole, D.2
Guan, X.3
|